Shenzhen Edge Medical Co., Ltd. (Stock Code: 2675) has announced the full exercise of the Over-allotment Option, involving 4,158,300 H Shares at HK$43.24 per H Share. The Over-allotment Shares represent approximately 15% of the total Offer Shares under the Global Offering and will be used to facilitate delivery to placees who agreed to delayed delivery.

Upon completion, the total number of shares in issue will increase from 387,722,200 to 391,880,500. The company expects to receive additional net proceeds of approximately HK$172.60 million from this exercise, to be allocated on a pro rata basis as stated in the Prospectus. The listing and dealings in the Over-allotment Shares on the Hong Kong Stock Exchange are scheduled to commence on February 9, 2026.

The announcement also confirms that the stabilization period for the Global Offering ended on February 4, 2026, with no shares being bought or sold on the market for price stabilization. Shenzhen Edge Medical Co., Ltd. remains in compliance with relevant public float requirements following the exercise of the Over-allotment Option.